Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2020

Equity [Abstract]

Schedule of Shares Repurchased

The table below summarizes the shares of our Common Stock we repurchased during 2020 under the program and the cost of the shares received, which were recorded as Treasury Stock.

	Three Months Ended September 30, 2020		Nine Months Ended September 30, 2020
Number of shares repurchased	179,824		898,991
Total cost of shares received	$	100.4	$	373.3

The table below summarizes the shares of our Common Stock Sanofi elected to sell, and we elected to purchase, to satisfy Sanofi's funding obligations and the cost of the shares received, which were recorded as Treasury Stock.

	Three Months Ended September 30,			Nine Months Ended September 30,
	2020	2019		2020		2019
Libtayo:
Number of shares purchased (by issuing a credit towards the amount owed by Sanofi)	—	103,761		77,677		210,733
Total cost of shares received	—	$	29.2	$	41.7	$	73.3
Dupilumab/Itepekimab:
Number of shares purchased (in cash)	—	69,143		171,471		93,286
Total cost of shares received	—	$	19.4	$	93.3	$	29.4